Opinions on GME, AMC, EXPR, NAKD, LIVE, KOSS this week

Since the Wallstreetbets site is getting pretty crowded, we are going to use this blog as a place to store more DD. 

GME - it's only a matter of time before short sellers crack. Hard to borrow rates are heavy. If you can, consider shorting low priced puts. March 19th put options strike price $20 are trading at $4. This is easy money that's pretty much guaranteed. Even if the shorts are successful in pushing down the price, there is no way they are getting it to $20 in six weeks. The best upside is buying stock. Call options are getting pricey. Another good thing is that insiders aren't sell and management isn't diluting. GME has a $100 million shelf offering out:

https://www.sec.gov/Archives/edgar/data/1326380/000119312520312805/d67321d424b5.htm

Even if they were to do a financing for the full $100 million, this is only around 300,000 shares at current prices. The worry of dilution is minimal here. 

AMC - Don't buy AMC. They are in bed with Goldman Sachs. Read this filing from this week:

https://www.sec.gov/Archives/edgar/data/1411579/000110465921006891/tm214013-1_424b5.htm


So if you buy AMC, you aren't screwing hedge funds shorting the stock, you're just helping Goldman Sachs make money. AMC has 45 million shares short. Well, the financing is for 50 million shares. That means shorts don't have to cover by buying your shares at a high price, they can just buy them off of Goldman at whatever price they set. Why do you want to support a company that doesn't care about you, that just wants to get money to pay management salaries and make Goldman Sachs money?

This is also a lot worse than GME which would have only a few hundred thousand shares issued for their $100 million. Don't split money between GME and AMC. AMC doesn't deserve it based on these actions.

EXPR - if you must buy something other than GME, EXPR is a lot better choice than AMC. It may have less shares short at 7 million or 13% of the float, but it also has no financing out. That means the only way for shorts to cover is to buy shares from people on the open market. It's not like the hedge funds can go to Goldman Sachs and ask for EXPR shares like they can for AMC shares. 

NAKD - don't buy this or waste time on this stock. Look at the stock price from 10 years ago. It went from $5,000 to less than $2. NAKD has done multiple reverse splits and heavy dilution. They are in bed with the hedge funds to get money, but must worse than AMC. They already released another share offering prospectus for 29 million shares on Friday, and they work with Maxim, one of the worst brokers for small caps to work with because the share price gets slaughtered. 


LIVE and KOSS - these two are small float runners, instead of heavy short interest plays. KOSS already ran over $100 from less than $10 and LIVE can have the same potential from $25. These two are okay because their floats are so small that putting a little bit of money here won't really impact your ability to buy and hold GME. KOSS ran over $100 on January 28th on only 11 million volume. LIVE has volume of less than a million and if it got to 10 million volume in a day it would probably run like KOSS too. Unlike AMC where it needs 500 million or a billion volume just to make it to $20. That's too much money to throw at AMC for it to move so little. 

Live Ventures Incorporated is a mix between GME and KOSS. It has a business like GME and a float like KOSS. 

This is KOSS's share stats from Yahoo:











This is LIVE's share stats from Yahoo:












LIVE's float is actually much less than KOSS, 1.26 million versus 3.72 million. LIVE also has more short interest, 79.52K or 6% of the float versus KOSS with 12.76K or less than 1% of the float. 

LIVE owns Vintage Stock. Vintage Stock is a retailer like GameStop that sells Music, Movies, Video Games, Comic Books, Posters, Toys and Sports Cards. It has about 60 locations across the southern United States. 

https://vintagestock.com/

LIVE also has really good financials, it has only an 8 PE ratio. Most companies have a PE ratio of 20 or more. 

Can this one go to $1,000? Or at least $100. We think so. 

LIVE is also big because unlike AMC and NAKD, it's not diluting, it's buying back stock instead. Look at the share float drop from 2 million to 1.5 million over the last two years. 

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more